CzeekV インデックス 活用事例・実践,研究報告など、お役立ち情報をシェアします

論文・技術情報追加のお知らせ

• 論文・技術情報追加のお知らせ

  2025年9月14日～2025年9月20日の間に収集した論文情報を追加しました。

  1. Investigation of Infection Risk Associated with Janus Kinase Inhibitors: A Pharmacovigilance Analysis Using the Food and Drug Administration's Adverse Event Reporting System Database.

  JAK阻害薬で感染有害事象多様、年齢性差考慮必要

  対象DB：FAERS

  2. Anticancer Drugs Associated With Tumor Lysis Syndrome: Insights From the US Food and Drug Administration Adverse Event Reporting System.

  FAERSでTLSと118薬の関連、ベネトクラックス突出

  対象DB：FAERS

  3. Adverse Events of Immune Checkpoint Inhibitors in Cancer Patients with Comorbid Diabetes: A Real-World Pharmacovigilance Analysis of the FDA Adverse Event Reporting System Database (2011-2025).

  糖尿病合併癌でICI有害事象増悪、早期発現傾向

  対象DB：FAERS

  4. Medications as precipitating factors for potential eating disorders: A disproportionality analysis using FDA adverse event reports.

  FAERSで摂食障害のシグナル、9薬剤抽出

  対象DB：FAERS

  5. Risk assessment of the top 60 drugs for drug-related sexual dysfunction: a disproportion analysis from the Food and Drug Administration adverse event reporting system.

  FAERSで性機能障害のシグナル、34薬剤特定

  対象DB：FAERS

  6. Rising Food and Diet Adverse Events in US Children: A Call for Better Food Labeling and Nutrition Documentation.

  CAERSで若年の重篤AE急増、表示とEMR標準化必要

  対象DB：FAERS

  7. Oral Anticoagulant Drugs and CNS-related Hematomas: a Pharmacovigilance Analysis from the FAERS Database.

  全OACでCNS血腫の薬剤監視シグナル、危険因子特定

  対象DB：FAERS

  8. Immune checkpoint inhibitor-induced vitiligo: A large-scale real world pharmacovigilance study.

  ICIで白斑の薬剤監視シグナル確認、予後関連示唆

  対象DB：FAERS

  9. An analysis of the association between atypical antipsychotic drugs and glaucoma risk: a disproportionality assessment based on the FAERS database.

  オランザピンで閉塞隅角緑内障のシグナル顕著

  対象DB：FAERS

  10. Adverse Events Associated With Dabrafenib, Trametinib, and Their Combination Therapy: A Disproportionality Analysis of the FDA Adverse Event Reporting System (FAERS) Database.

  D/T併用で眼・心血管AE増、単剤差異も確認

  対象DB：FAERS

  11. Pharmacovigilance-based 12-year post-marketing safety analysis of quadrivalent influenza vaccines in children: a VAERS surveillance study.

  小児QIVは概ね安全、GBS稀にシグナル検出

  対象DB：FAERS,VAERS

  12. Real-world safety comparison between cenobamate and lacosamide: a pharmacovigilance study based on the FDA Adverse Event Reporting System.

  CNB/LCMのFAERS比較で有害事象差異確認

  対象DB：FAERS

  13. Adverse events of ursodeoxycholic acid: a real-world pharmacovigilance study using FAERS (2004-2023).

  UDCAのFAERS解析で新規AEシグナル提示

  対象DB：FAERS

  14. Real-World Safety of Apremilast: A Pharmacovigilance Analysis Using the FDA Adverse Event Reporting System (FAERS).

  FAERSでアプレミラスト安全性解析報告

  対象DB：FAERS

  15. Analyzing real-world adverse events of spironolactone with the FAERS database.

  FAERSでスピロノラクトン新規稀AEシグナル検出

  対象DB：FAERS

  16. Evaluating the toxicity profile of combination immune checkpoint inhibitors: a disproportionality analysis of real-world adverse events from the FDA Adverse Event Reporting System for tremelimumab, durvalumab, ipilimumab, and nivolumab.

  併用ICIで免疫関連毒性増、CRS強シグナル注意

  対象DB：FAERS

  17. Disproportionality analysis of ixekizumab-associated adverse events in the FAERS database: A real-world pharmacovigilance study.

  FAERSでイキセキズマブAE網羅、新規事象も確認

  対象DB：FAERS

  18. A real-world pharmacovigilance assessment of drug-related carcinoembryonic antigen increase.

  CEA上昇薬49種特定、高齢女性で多発傾向

  対象DB：FAERS

  19. A real-world data analysis of Ozanimod in the FDA Adverse Event Reporting System (FAERS) database.

  FAERSでオザニモドAE網羅、30日内多発傾向確認

  対象DB：FAERS

  20. Exploring drug-induced pemphigus findings from the FDA adverse event reporting system database.

  FAERSで天疱瘡強シグナル薬特定、早期発現傾向示唆

  対象DB：FAERS

  21. Mechanistic insights into taxane-induced psychiatric adverse events: a global pharmacovigilance and experimental investigation.

  タキサン系で精神症状シグナル、若年女性・乳癌で高リスク

  対象DB：FAERS,VigiBase

  22. Pharmacovigilance-Based Identification and Mechanistic Exploration of Periodontitis-Related Drugs.

  FAERSで薬剤と歯周病関連、VEGFA媒介示唆

  対象DB：FAERS

  23. Characterizing the FDA Adverse Event Reporting System (FAERS) as a Network to Improve Pattern Discovery.

  FAERSをNAで網羅解析、重尾分布と有用性示唆

  対象DB：FAERS,VAERS

  24. Negative outcomes associated with tyrosine kinase inhibitors during management of gastrointestinal stromal tumors: examination of data from the FDA adverse event reporting system.

  GIST向けTKIで薬剤別AEを特定、特徴把握促進

  対象DB：FAERS

  25. Alopecia as an Emerging Adverse Effect Associated With Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists for Weight Loss: A Scoping Review.

  GLP-1RAで脱毛報告増加、因果未確定も注意喚起必要

  対象DB：FAERS

  26. Adverse drug events associated with tiotropium: a real-world pharmacovigilance study of FDA adverse event reporting system database.

  チオトロピウムで新規AEシグナル検出、注意喚起

  対象DB：FAERS

  27. Risk of interstitial lung disease in non-small cell lung cancer treated with EGFR-TKI: a real-world pharmacovigilance study.

  EGFR-TKIでILDシグナル、年齢・脂質異常・ランソプラゾールでリスク増加

  対象DB：FAERS

  28. Decoding fatal toxic effects in checkpoint inhibitor therapy using real-world pharmacovigilance data and machine learning.

  ICIで多臓器致死irAE特定、MLで90日死亡予測成功

  対象DB：FAERS

  29. Sequence Symmetry Analysis of the Interrelationships Between Ramelteon and Parkinson's Disease.

  ラメルテオン使用でPD発症抑制示唆、慎重解釈必要

  対象DB：DeSC,FAERS

  30. Analysis of pulmonary adverse events associated with immune checkpoint inhibitors based on FAERS and VigiBase database.

  ICI開始60日内に肺免疫関連AE多発、致死率高い

  対象DB：FAERS,VigiBase

  31. Analysis of Adverse Drug Reactions of Clofazimine Reported in the FDA Adverse Event Reporting System from 2004 to 2025 Q1.

  クロファジミンでQT延長等の強信号、重篤例多い

  対象DB：FAERS

  32. Do Postoperative Outcomes of Surgical Treatment for Spinal Metastasis Differ by Institutional Function?: Analysis of a Nationwide Administrative Database in Japan.

  がんセンター・高症例病院で30日死亡率低下

  対象DB：DPC

  33. Adherence to monitoring iron indices at the initiation of erythropoiesis-stimulating agents or hypoxia-inducible factor prolyl hydroxylase inhibitors.

  鉄欠乏指標検査の順守は施設種別で差大、改善余地あり

  対象DB：DPC,DeSC

  34. Epidemiology and Risk Factors of Pediatric Clostridioides difficile Infection: A Nationwide Claims-based Comparison With Adults in Japan.

  小児CDIは乳幼児でも発生、抗菌薬なしも多い

  対象DB：JMDC

  35. Weight trajectories and access to weight management services in individuals with severe mental illness in the UK: a population-based, matched cohort study.

  重度精神疾患で長期体重増、紹介不足継続

  対象DB：CPRD

  36. Associations between falls and other serious adverse events and antihypertensive medication in individuals with dementia: An observational cohort study.

  認知症で降圧薬の有害事象絶対リスク高い

  対象DB：CPRD

  37. Validation of the transformed clinical practice research datalink (CPRD) GOLD and aurum data into the OMOP common data model.

  CPRD→OMOP変換で件数整合性高く信頼可

  対象DB：CPRD

  38. Real-world Comparative Effectiveness in Patients with Asthma Newly Initiating Fluticasone Furoate/Vilanterol or Budesonide/Formoterol: A United Kingdom General Practice Cohort Study.

  FF/VIはBUD/FORより増悪・中止・OCS減少

  対象DB：CPRD

  39. Trends in first-line monotherapy and combination therapy for hypertension in UK primary care.

  英国では初期併用療法稀で持続性低い

  対象DB：CPRD

  40. The diagnostic status of chronic kidney disease in a real-world database in Japan: CHECK-CKD.

  日本でCKD診断率低迷、早期検査で早期発見促進

  対象DB：DeSC

  タグ:

  • お知らせ
  • 論文

• お問合わせ

  お問合わせ

  検索

  サイト内検索・論文検索

  

  検索

  サイト内 論文

  キーワード

  PubmedID
  Abstract
  Title
  Journal
  Date (PubMed追加日)	～
  Author
  タクソノミー検索	タクソノミー検索 CAERS CARD CPRD CVAR CVARD DeSC DPC EHR EudraVigilance FAERS Fibroblasts FPVD GPRD Ionizing JADER JMDC KAERS KIDS-KAERS KIDS-KD MDV NDB Nickel Pharmacoepidemiology Radiation RWE THIN Unknown VAERS VigiBase インフォメーション スコア値 スコア指標 総合ランキング 閾値

  

  メルマガ登録

  購読申し込み